JP5695826B2 - Enzyme processing method for horse or sheep myocardium, food material, and health food for immunostimulation, tonicity, and metabolism promotion - Google Patents
Enzyme processing method for horse or sheep myocardium, food material, and health food for immunostimulation, tonicity, and metabolism promotion Download PDFInfo
- Publication number
- JP5695826B2 JP5695826B2 JP2009299070A JP2009299070A JP5695826B2 JP 5695826 B2 JP5695826 B2 JP 5695826B2 JP 2009299070 A JP2009299070 A JP 2009299070A JP 2009299070 A JP2009299070 A JP 2009299070A JP 5695826 B2 JP5695826 B2 JP 5695826B2
- Authority
- JP
- Japan
- Prior art keywords
- horse
- myocardium
- enzyme
- sheep
- sheep myocardium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004190 Enzymes Human genes 0.000 title claims description 35
- 108090000790 Enzymes Proteins 0.000 title claims description 35
- 210000004165 myocardium Anatomy 0.000 title claims description 35
- 241000283073 Equus caballus Species 0.000 title claims description 27
- 241001494479 Pecora Species 0.000 title claims description 20
- 235000013305 food Nutrition 0.000 title claims description 8
- 239000000463 material Substances 0.000 title claims description 6
- 235000013402 health food Nutrition 0.000 title claims description 5
- 230000003308 immunostimulating effect Effects 0.000 title claims description 4
- 230000004060 metabolic process Effects 0.000 title claims description 4
- 238000003672 processing method Methods 0.000 title description 2
- 238000006243 chemical reaction Methods 0.000 claims description 38
- 108010022999 Serine Proteases Proteins 0.000 claims description 15
- 102000012479 Serine Proteases Human genes 0.000 claims description 15
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 12
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 150000001413 amino acids Chemical group 0.000 claims description 7
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 230000007515 enzymatic degradation Effects 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 28
- 229940088598 enzyme Drugs 0.000 description 28
- 239000000843 powder Substances 0.000 description 18
- 210000000822 natural killer cell Anatomy 0.000 description 14
- 108090000317 Chymotrypsin Proteins 0.000 description 13
- 229960002376 chymotrypsin Drugs 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000002107 myocardial effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000004726 Connectin Human genes 0.000 description 5
- 108010002947 Connectin Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000000593 degrading effect Effects 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 238000011105 stabilization Methods 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 102000018832 Cytochromes Human genes 0.000 description 3
- 108010052832 Cytochromes Proteins 0.000 description 3
- 241000272168 Laridae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000036675 Myoglobin Human genes 0.000 description 3
- 108010062374 Myoglobin Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 241000283086 Equidae Species 0.000 description 2
- 102000008015 Hemeproteins Human genes 0.000 description 2
- 108010089792 Hemeproteins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- QHKHVKLZWAKLMU-UHFFFAOYSA-N 2-(2-amino-3-hydroxyphenyl)propanoic acid Chemical compound NC1=C(C=CC=C1O)C(C(=O)O)C QHKHVKLZWAKLMU-UHFFFAOYSA-N 0.000 description 1
- KYNMONSTYCGIDJ-UHFFFAOYSA-N 2-amino-3-(1h-indol-2-yl)propanoic acid Chemical compound C1=CC=C2NC(CC(N)C(O)=O)=CC2=C1 KYNMONSTYCGIDJ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- -1 aromatic amino acid Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009661 fatigue test Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Description
本発明は、馬、又は、羊の心筋を加水分解処理し低分子ペプチドを製造し、機能性健康・食品素材として供する技術に関するものである。 The present invention relates to a technique for producing a low molecular weight peptide by hydrolyzing horse or sheep myocardium and providing it as a functional health / food material.
動物エキス、動物内蔵乾燥末などが栄養食品、健康食品に使用されている。これらを摂取することによる効果は、これらに含有される蛋白質の有用性にあるといえるが、得てして蛋白質の分子量が大きく、人が摂取しても体内での吸収、機能面で質的、量的に問題があった。そこで、本発明者らは、動物心筋の強壮作用、免疫向上効果について研究した。その結果、動物心筋から得られる心筋ペプチド混合物を継続摂取することによって、免疫賦活、強壮改善作用が促進されることを明らかにした。 Animal extracts and dry powder with built-in animals are used for nutritional and health foods. Although the effects of ingesting these are due to the usefulness of the proteins contained in them, the resulting protein has a large molecular weight, and even if it is ingested by humans, it is absorbed and functionally qualitatively and quantitatively. There was a problem. Therefore, the present inventors studied the tonic action and immunity improvement effect of animal myocardium. As a result, it was clarified that immunity activation and tonic improvement were promoted by continuously ingesting a myocardial peptide mixture obtained from animal myocardium.
なお、本発明に関連した先行技術文献としては、特許文献1〜6があげられる。特許文献1には、哺乳動物の心臓などを磨細し、自己消化させたのちに処理するという「抗脂血作用を有する物質の製造法」が開示されている。特許文献2には、鶏ガラを常圧加熱水加熱しチキンエキスを得た後、抽出残渣に水を加え加圧熱水加熱してチキンエキスを得、ついで両エキスを混合するという「チキンエキスの製造方法」が開示されている。特許文献3には、エキス固形分濃度0.5〜10%程度に熱水抽出した抽出液を過熱温度90℃以下かつ蒸発温度60℃以下の条件で濃縮するという「濃縮エキスの製造方法」が開示されている。特許文献4には、(i)鳥ガラまたは鳥ガラとその肉を熱水抽出する工程、(ii)抽出液からオイルを除去する工程、(iii)オイル除去された抽出液に含まれている鳥ガラをミンチする工程、(iv)オイル除去された抽出液と鳥ガラミンチよりなる組成物を酵素分解する工程、よりなる「鳥エキスの製法」が開示されている。特許文献に5は、動物心臓を酵素処理して得られる心臓ペプチド混合物からなる「肝臓脂質代謝改善剤」が開示されている。そして、特許文献6には、鳥獣畜肉に対して糖類の存在下に鰹節菌の作用により得られる「鳥獣畜肉発酵加工食品」が開示されている。 In addition, patent documents 1-6 are mention | raise | lifted as a prior art document relevant to this invention. Patent Document 1 discloses “a method for producing a substance having an antilipidemic effect” in which a mammal's heart or the like is polished and self-digested before being processed. Patent Document 2 discloses that a chicken extract is obtained by heating chicken fry with atmospheric pressure heating water to obtain a chicken extract, adding water to the extraction residue and heating with pressurized hot water to obtain a chicken extract, and then mixing both extracts. Is disclosed. Patent Document 3 discloses a “concentrated extract production method” in which an extract extracted with hot water to an extract solids concentration of about 0.5 to 10% is concentrated under conditions of a superheating temperature of 90 ° C. or less and an evaporation temperature of 60 ° C. or less. It is disclosed. Patent Literature 4 includes (i) a bird gull or a step of hot water extraction of a bird gull and its meat, (ii) a step of removing oil from the extract, and (iii) an extract from which oil has been removed. There is disclosed a “bird extract manufacturing method” comprising a step of mincing a bird gall, (iv) a step of enzymatically decomposing a composition comprising an oil-removed extract and a bird gull mince. Patent Document 5 discloses a “liver lipid metabolism improving agent” comprising a heart peptide mixture obtained by enzymatic treatment of animal heart. Patent Document 6 discloses “avian and livestock fermented processed foods” obtained by the action of koji fungus in the presence of saccharides on wild and livestock meat.
ところで、蛋白質は分子量が大きく、人が摂取しても体内での吸収、機能面で質的、量的に問題があるという点に対しては、前記のとおり、心筋ペプチド混合物を継続摂取すること、即ち、動物心筋の弾性蛋白質コネクチン、ミオグロビン、チトクロームCなどを含む蛋白質をペプチド化し、食品、健康食品として摂取するという解決策がある。しかし、蛋白質を分解してペプチド化すれば、免疫賦活、強壮、代謝促進作用が改善されることは明らかであるが、動物心筋を加水分解処理するに当り、処理に関わる反応制御に改善すべき点があり、このため生産物(ペプチド含有製品)の、均一性、風味、吸収性、機能性の点で問題があった。 By the way, as described above, protein has a large molecular weight, and even if it is ingested by humans, there is a problem in terms of absorption and function in the body. That is, there is a solution in which a protein containing an animal myocardium elastic protein connectin, myoglobin, cytochrome C, etc. is peptideized and taken as food or health food. However, it is clear that degrading proteins into peptides to improve immunostimulation, tonicity, and metabolism-promoting effects should be improved when controlling animal myocardial hydrolysis. For this reason, there was a problem in terms of uniformity, flavor, absorbability, and functionality of the product (peptide-containing product).
従って、本発明は、反応制御を改善した馬、又は、羊の心筋の酵素処理方法などを提供することを課題とする。 Accordingly, the present invention provides a horse improved reaction control, or, it is an object to provide a like enzyme treatment method sheep myocardium.
本発明者らは、動物心筋のコネクチン、ミオグロビン、チトクロームCなどを含む蛋白質を加水分解することによりペプチド混合物を得るため、アルカラーゼ、システインプロテアーゼ、ニュートラーゼ、セリンプロテアーゼ、ペプチターゼ、パンクレアチン、プロテアーゼ、リバーゼ、について、これら酵素を1種類添加又は2種類添加あるいは同時添加の研究を行ったが、条件面で問題があることを見出した。 In order to obtain a peptide mixture by hydrolyzing a protein containing connectin, myoglobin, cytochrome C and the like of animal myocardium, the present inventors have obtained an alcalase, a cysteine protease, a neutralase, a serine protease, a peptidase, a pancreatin, a protease, and a ribase. Regarding the above, studies were made on the addition of one or two of these enzymes or the simultaneous addition of these enzymes.
そこで、本発明者らは種々検討した結果、2種類の分解酵素を、その酵素の特性に合わせ、第一段階、第二段階と個々に分解酵素を単独に至適分解温度、至適pH値(水素イオン濃度値)を設定し至適相対活性で作用させることで、安定した分解に至ることを見出した。更に、生産物の機能性を高めるためキモトリプシン分解酵素でチロシン、フェニルアラニン、トリプトファンのカルボキシル基の関与するペプチド結合を分解することにより、よりペプチドの機能性が高まり、様々な食品に機能性を付与することができることを見出した。 Therefore, as a result of various studies, the present inventors adjusted two kinds of degrading enzymes according to the characteristics of the enzymes, the first stage, the second stage and the individual degrading enzymes individually, the optimum decomposition temperature, the optimum pH value. It was found that stable decomposition can be achieved by setting (hydrogen ion concentration value) and causing it to act at an optimum relative activity. Furthermore, by improving the functionality of the product, the peptide bond involving the carboxyl group of tyrosine, phenylalanine, and tryptophan is degraded by chymotrypsin degrading enzyme, thereby increasing the functionality of the peptide and adding functionality to various foods. I found that I can do it.
本発明者らは、かかる知見に基づき、馬、又は、羊の心筋を加水分解する際に反応効率を向上させるべく、馬、又は、羊の心筋に対して、段階的加水分解処理を行うことにより反応制御性が改善されることに着目し、本発明を完成させるに至った。即ち、本発明は、馬、又は、羊の心筋を加水分解処理するに当って心筋の性質と酵素の特性(例えば:反応制御のし易さ、連続性、生産物の均一化条件)を保持しつつ馬、又は、羊の心筋の加水分解が効率よく行われるようにしたことを特徴とする。 The present inventors, based on the above findings, horses, or sheep myocardium to improve the reaction efficiency when hydrolysis, equine, or, for the sheep heart muscle, by performing the step hydrolysis process Focusing on the improvement in reaction controllability, the present invention has been completed. That is, the present invention retains the properties of the myocardium and the properties of the enzyme (eg, ease of reaction control, continuity, product homogenization conditions) in hydrolyzing the myocardium of horses or sheep. However, it is characterized in that the myocardium of the horse or sheep is efficiently hydrolyzed.
更に、生成した心筋に由来するペプチド混合物を含有する物を主成分としたもので免疫賦活、強壮作用、新陳代謝改善促進剤として機能性食品を製造できることに着目して本発明を完成させるに至った。 Moreover, immunostimulatory those containing peptide mixture derived from the generated myocardium those mainly, tonic, and completed the present invention by paying attention to possible to manufacture a functional food as metabolism improving accelerator .
本発明によれば、反応制御を改善した馬、又は、羊の心筋の酵素処理方法などを提供することができる。 ADVANTAGE OF THE INVENTION According to this invention, the enzyme processing method etc. of the horse or sheep myocardium which improved reaction control can be provided.
以下、本発明を実施するための形態(実施形態)を説明する。
本発明を実施するに当り、第一段階の反応では、セリンプロテアーゼ酵素の特性に分解反応条件を設定し酵素分解を行い酵素分解終了後、酵素を失活させた。更に、第二段階の反応では、システインプロテアーゼ酵素の特性に分解反応条件を設定して分解を行い終了後、第一段階と同様に酵素を失活させた。
Hereinafter, modes (embodiments) for carrying out the present invention will be described.
In practicing the present invention, in the first stage reaction, the degradation reaction conditions were set for the properties of the serine protease enzyme, the enzyme degradation was performed, and the enzyme was inactivated after the completion of the enzyme degradation. Furthermore, in the second stage reaction, the degradation reaction conditions were set in the characteristics of the cysteine protease enzyme and the degradation was completed. Then, the enzyme was deactivated in the same manner as in the first stage.
更に、第二段階の後、第三段階の反応では、キモトリプシン酵素でチロシン、フェニルアラニン、トリプトファンのカボキシル基の関与するペプチド結合を分解させ、基質となる心筋蛋白質の機能向上あるいは新機能性を付加させた。
なお、ペプチド結合は、アミド結合(アミンと有機酸の脱水素結合)のうち、アミノ酸同士が脱水縮合して形成される結合である。多数のアミノ酸が縮合した高分子物質はタンパク質である。
Furthermore, after the second stage, in the third stage reaction, peptide bonds involving tyrosine, phenylalanine and tryptophan carboxyl groups are degraded by chymotrypsin enzyme to improve the function of myocardial protein as a substrate or add new functionality. It was.
The peptide bond is a bond formed by dehydration condensation of amino acids among amide bonds (dehydrogen bond between amine and organic acid). A macromolecular substance in which a large number of amino acids are condensed is a protein.
分解酵素の段階的組み合わせはセリンプロテアーゼとシステインプロテアーゼ及びキモトリプシン又はセリンプロテアーゼとキモトリプシン、システインプロテアーゼとキモトリプシンの組み合わせで行ってもよい。本発明の対象となる食品は本組成を損なわない範囲で粉末単独あるいは適宜に配合できる。以下実施例を挙げ、本発明を説明するが本発明はこれらの実施例に限定されるものではない。
ちなみに、後記する実施例1と実施例2では、下記の表1に示す酵素を選択使用した。実施例2では、第三段階の反応=第二段階の反応である。
補足すると、第一段階の反応では、セリンプロテアーゼを好適に用いることができる。また、第二段階の反応では、システインプロテアーゼを好適に用いることができる。また、第三段階の反応では、キモトリプシンを好適に用いることができる。
The stepwise combination of degrading enzymes may be performed by serine protease and cysteine protease and chymotrypsin or serine protease and chymotrypsin, or a combination of cysteine protease and chymotrypsin. The food which is the object of the present invention can be blended with the powder alone or appropriately as long as the composition is not impaired. EXAMPLES Hereinafter, the present invention will be described with reference to examples, but the present invention is not limited to these examples.
Incidentally, in Examples 1 and 2 described later, enzymes shown in Table 1 below were selectively used. In Example 2, the third stage reaction = the second stage reaction.
Supplementally, a serine protease can be suitably used in the first stage reaction. In the second stage reaction, cysteine protease can be preferably used. In the third stage reaction, chymotrypsin can be preferably used.
なお、後記する実施例5におけるNK細胞活性(図2中の「NK活性(%)」)は、ナチュラルキラー細胞(NK細胞)の活性を示すものである。ここで、NK細胞とは、先天免疫の主要因子として働く細胞傷害性リンパ球の一種であり、特に腫瘍細胞やウィルス感染細胞の拒絶に重要である。NK細胞は、これらの悪性の細胞を殺すのにT細胞とは異なり事前に感作させておく必要がないということから、つまり、抗原感作なしに腫瘍細胞やウィルス感染細胞などを殺す(傷害する)ことから、NK(natural killer cell)と名付けられている。 In addition, the NK cell activity in Example 5 described later (“NK activity (%)” in FIG. 2) indicates the activity of natural killer cells (NK cells). Here, NK cells are a kind of cytotoxic lymphocytes that act as a major factor of innate immunity, and are particularly important for rejection of tumor cells and virus-infected cells. NK cells, unlike T cells, do not need to be sensitized beforehand in order to kill these malignant cells. That is, they kill tumor cells and virus-infected cells without antigen sensitization (injury). Therefore, it is named NK (natural killer cell).
(酵素について)
第一段階の反応に使用される「セリンプロテアーゼ(serine protease)」は、触媒残基として求核攻撃を行うセリン残基をもつプロテアーゼ(蛋白質分解酵素)である。また、第二段階の反応に使用される「システインプロテアーゼ(cysteine protease)」は、触媒部位において、システインのチオール基を求核基として用いる蛋白質分解酵素である。また、第三段階の反応に使用される「キモトリプシン(chymotrypsin)」は、エンドペプチダーゼ、セリンプロテアーゼの一種、かつ、膵液に含まれる消化酵素の一種であり、芳香族アミノ酸のカルボキシル基側のペプチド結合を加水分解する。
(About enzymes)
The “serine protease” used in the first stage reaction is a protease (proteolytic enzyme) having a serine residue that performs a nucleophilic attack as a catalytic residue. The “cysteine protease” used in the second stage reaction is a proteolytic enzyme that uses the thiol group of cysteine as a nucleophilic group at the catalytic site. In addition, "chymotrypsin" used in the third stage reaction is a kind of endopeptidase, a serine protease, and a digestive enzyme contained in pancreatic juice, and is a peptide bond on the carboxyl group side of an aromatic amino acid. Is hydrolyzed.
(アミノ酸について)
また、「チロシン(tyrosine)」は、アミノ酸の一種であり、側鎖にフェノール部位を持つ。2-アミノ-3-ヒドロキシフェニルプロピオン酸あるいは p-ヒドロキシフェニルアラニンとも呼ばれる。この分子式は、「C9H11NO3」である。また、「フェニルアラニン(phenylalanine)」も、アミノ酸の一種であり、側鎖にベンジル基を持つ。この分子式は、「C9H11NO2」である。また、「トリプトファン(tryptophan)も、アミノ酸の一種であり、2-アミノ-3-(インドリル)プロピオン酸のことである。分子式は、「C11H12N2O2」である。これらは、いずれも、カルボキシル基(COOH)を有する。
(About amino acids)
"Tyrosine" is a kind of amino acid and has a phenol moiety in the side chain. Also called 2-amino-3-hydroxyphenylpropionic acid or p-hydroxyphenylalanine. The molecular formula is “C 9 H 11 NO 3 ”. “Phenylalanine” is also a kind of amino acid and has a benzyl group in the side chain. The molecular formula is “C 9 H 11 NO 2 ”. “Tryptophan” is also a kind of amino acid, and is 2-amino-3- (indolyl) propionic acid. The molecular formula is “C 11 H 12 N 2 O 2 ”. All of these have a carboxyl group (COOH).
(蛋白質について)
「コネクチン(connectin)」はタイチンともいい、横紋筋のZ線とM線を1分子でつなぐ弾性蛋白質であり、非常に大きな分子量の分子である。また、「ミオグロビン(myoglobin)」は、主に心筋や骨格筋に存在する分子量約17500のヘム蛋白であり、筋肉中にあって酸素分子を代謝に必要な時まで貯蔵する。また、「チトクロームC(cytochrome C)」は、筋肉中に存在する分子量約12400の分子であり、酸化還元機能を持つヘム鉄を含有するヘム蛋白質の一種である。
(About protein)
“Connectin”, also called titin, is an elastic protein that connects the Z-line and M-line of the striated muscle with a single molecule, and has a very large molecular weight. In addition, “myoglobin” is a heme protein having a molecular weight of about 17500, which is mainly present in the heart muscle and skeletal muscle, and stores oxygen molecules until they are necessary for metabolism in the muscle. Further, “cytochrome C” is a molecule having a molecular weight of about 12400 present in muscle and is a kind of heme protein containing heme iron having a redox function.
≪実施形態1≫
実施形態1では、後記するように、馬心筋を対象として、温度調節機能付きの容器により第一段階の反応と、それに続く第二段階の反応と、更にそれに続く第三段階の反応を行った。
第一段階の反応では、酵素としてセリンプロテアーゼを用いた。セリンプロテアーゼは、相対活性における至適pH−活性値はpH7.0、温度−活性至適は50〜55℃という特性を有するので第一段階の反応に好適に用いることができる。
第二段階の反応では、酵素としてシステインプロテアーゼを用いた。システインプロテアーゼは、相対活性における至適pH−活性値はpH6.5、温度−活性至適は80℃という特性を有するので第二段階の反応に好適に用いることができる。
第三段階の反応では、酵素としてキモトリプシンを用いた。キモトリプシンは、相対活性における至適pH−活性値はpH7.5、温度−活性至適は50℃という特性を有するので第三段階の反応に好適に用いることができる。
4倍量の水を用いたのは、蛋白の拡散性、分散性、添加酵素の反応性を考慮したものである。水が多いと生産性が低下する。一方、水が少ないと酵素の反応性が低下する。
Embodiment 1
In the first embodiment, as will be described later, the first-stage reaction, the subsequent second-stage reaction, and the subsequent third-stage reaction were performed using a container with a temperature control function for horse myocardium. .
In the first stage reaction, serine protease was used as the enzyme. Serine protease has the characteristics that the optimum pH-activity value in relative activity is pH 7.0, and the temperature-activity optimum is 50-55 ° C., so it can be suitably used for the first stage reaction.
In the second stage reaction, cysteine protease was used as the enzyme. Cysteine protease can be suitably used for the second stage reaction since it has the characteristics that the optimum pH-activity value in relative activity is pH 6.5 and the temperature-activity optimum is 80 ° C.
In the third stage reaction, chymotrypsin was used as an enzyme. Chymotrypsin has the characteristics that the optimum pH-activity value in relative activity is pH 7.5, and the temperature-activity optimum is 50 ° C., so it can be suitably used for the third stage reaction.
The use of 4 times the amount of water is due to consideration of protein diffusivity, dispersibility, and added enzyme reactivity. Productivity decreases when there is much water. On the other hand, when there is little water, the reactivity of an enzyme will fall.
≪実施形態2≫
実施形態2では、後記するように、羊心筋を対象として、温度調節機能付きの容器により第一段階の反応と、それに続く第二段階(=第三段階)の反応を行った。
第一段階の反応では、酵素としてセリンプロテアーゼを用いた。セリンプロテアーゼは、相対活性における至適pH−活性値はpH7.0、温度−活性至適は50〜55℃という特性を有するので第一段階の反応に好適に用いることができる。
第二段階(第三段階)の反応では、酵素としてキモトリプシンを用いた。キモトリプシンは、相対活性における至適pH−活性はpH7.5、温度−活性至適は50℃という特性を有するので第二段階の反応に好適に用いることができる。
3倍量の水を用いたのは、前記と同様である。
<< Embodiment 2 >>
In the second embodiment, as described later, for the sheep myocardium, the first-stage reaction and the subsequent second-stage (= third-stage) reaction were performed using a container with a temperature control function.
In the first stage reaction, serine protease was used as the enzyme. Serine protease has the characteristics that the optimum pH-activity value in relative activity is pH 7.0, and the temperature-activity optimum is 50-55 ° C., so it can be suitably used for the first stage reaction.
In the second stage (third stage) reaction, chymotrypsin was used as an enzyme. Chymotrypsin has the characteristics that the optimum pH-activity in relative activity is pH 7.5 and the temperature-activity optimum is 50 ° C., so it can be suitably used for the second stage reaction.
The use of three times the amount of water is the same as described above.
以下、前記実施形態を具体化した実施例を説明する。なお、本発明がこの実施例のみに限定されるものではないことは言うまでもない。 Hereinafter, examples embodying the embodiment will be described. Needless to say, the present invention is not limited to this embodiment.
実施形態1に対応する実施例1を説明する。実施例1では、馬心筋50kgをホモジナイズし、これを温度調節機能付きのステンレス製の適量の容器(反応槽)に入れ、これに4倍量の水を加水して、(第一段階)温度を50〜55℃に設定し、温度安定の後pH7.0に調製する。3〜5時間後再度pHを確認、調製しセリンプロテアーゼ1kgを加え、10時間酵素分解を行う。分解後80℃以上で40分間保持させ酵素を失活させ、(第二段階)次いで冷却し80℃に設定し、温度安定後にpH6.5に調製し、2〜5時間後再度pHを確認、調製し、システインプロテアーゼ1kgを加え10時間酵素分解後、80℃以上で40分間保持し酵素を失活させる。(第三段階)次いで冷却し、50℃に設定し、温度安定後pH7.5に調製しキモトリプシン400gを加え3〜5時間酵素分解を行った後、80℃以上で40分間保持し酵素を失活させ、不溶物を除去後、凍結乾燥して約43kgの粉末を得た。
なお、第一段階〜第三段階までの反応は、同一の反応槽で行った。
Example 1 corresponding to Embodiment 1 will be described. In Example 1, 50 kg of equine myocardium was homogenized and placed in an appropriate amount of a stainless steel container (reaction tank) with a temperature control function. Is set to 50-55 ° C. and is adjusted to pH 7.0 after temperature stabilization. 3 to 5 hours later, the pH is confirmed and adjusted again, 1 kg of serine protease is added, and enzymatic degradation is performed for 10 hours. After the decomposition, the enzyme is inactivated by maintaining at 80 ° C or higher for 40 minutes (second stage), then cooled and set to 80 ° C, adjusted to pH 6.5 after temperature stabilization, and the pH is confirmed again after 2 to 5 hours Prepare, add 1 kg of cysteine protease, enzymatically degrade for 10 hours, and hold at 80 ° C. or higher for 40 minutes to inactivate the enzyme. (Third stage) Next, cool, set to 50 ° C., adjust to pH 7.5 after temperature stabilization, add 400 g of chymotrypsin, perform enzymatic degradation for 3-5 hours, then hold at 80 ° C. or higher for 40 minutes to lose the enzyme. After removing the insoluble matter, the solution was freeze-dried to obtain about 43 kg of powder.
The reaction from the first stage to the third stage was performed in the same reaction tank.
実施形態2に対応する実施例2を説明する。実施例2では、羊心筋2kgをホモジナイズし、温度調節機能付きのガラス製の5リットル容器(反応槽)に入れ、これに3倍量の水を加水し、(第一段階)温度を50〜55℃に設定し、温度安定後pH7.0に調製し、2〜4時間後再度pHを調製してセリンプロテアーゼ40gを加え6〜8時間酵素分解を行った後、80℃以上で40分間保持させ酵素を失活させる。(第三段階(=第二段階))次いで温度を下げ50℃に設定して、温度安定後pH7.5に調製しキモトリプシン10gを加え3〜6時間酵素分解を行った後、80℃以上で30分間保持し酵素を失活させ、不溶物を除去後、凍結乾燥して約1.6kgの粉末を得た。
なお、この実施例2でも、各段階の反応は、同一の反応槽で行った。
ちなみに、実施例2では、システインプロテアーゼによる第二段階が存在しないが、これは、対象とした動物(馬と羊)の違いによるコネクチンを含む総蛋白質の分子量の違いに起因するものである。
Example 2 corresponding to Embodiment 2 will be described. In Example 2, 2 kg of sheep myocardium was homogenized and placed in a glass 5 liter container (reaction tank) with a temperature control function, to which 3 times the amount of water was added, and (first stage) the temperature was 50- Set to 55 ° C, adjust to pH 7.0 after temperature stabilization, adjust pH again after 2-4 hours, add serine protease 40g and perform enzymatic degradation for 6-8 hours, then hold at 80 ° C or higher for 40 minutes Inactivate the enzyme. (Third stage (= second stage)) Next, the temperature was lowered to 50 ° C., adjusted to pH 7.5 after temperature stabilization, 10 g of chymotrypsin was added, and enzymatic degradation was performed for 3 to 6 hours. The enzyme was inactivated by holding for 30 minutes to remove insoluble matters, and then freeze-dried to obtain about 1.6 kg of powder.
In Example 2, the reaction at each stage was performed in the same reaction tank.
Incidentally, in Example 2, the second step by cysteine protease does not exist, but this is due to the difference in the molecular weight of the total protein including connectin due to the difference in the target animals (horse and sheep).
凍結乾燥;
実施例2で得られた凍結乾燥前の液に松谷化学工業株式会社製のパインデックス(登録商標)#100を250g加え凍結乾燥して約1.8kgを得た。なお、パインデックスは澱粉を加水分解し、精製した高純度の澱粉分解物である。澱粉分解物を加えることにより、これが賦形剤となり、素材製品の保存性、溶解性、風味がより向上し他素材との配合により高い機能性食品とすることができる。
freeze drying;
250 g of Paindex (registered trademark) # 100 manufactured by Matsutani Chemical Industry Co., Ltd. was added to the liquid before freeze-drying obtained in Example 2 and freeze-dried to obtain about 1.8 kg. The paindex is a high-purity starch decomposition product obtained by hydrolyzing and purifying starch. By adding a starch degradation product, this becomes an excipient, which improves the preservability, solubility and flavor of the raw material product, and can be made into a highly functional food by blending with other raw materials.
抗疲労試験;
馬心筋粉末の肉体的抗疲労作用の評価としてマウスによる実験を行った。30匹のマウス(ddy、雄、6週齢)を、コントロール群(Cont)、朝鮮人参エキス末(市販品)群(100mg)、馬心筋粉末50、100、200mg/kg群の5群に分け飼育して、各粉末を水に分散し各投与量で、1日1回、2週間マウスに経口投与した。2週間目にマウス体重の10%の重りを負荷して、強制水泳実験(頭部が5秒間完全に水中に水没するまでの時間を測定した)を行った。結果投与2週間目の測定時で、馬心筋粉末投与群はコントロール群と比較して水泳持続時間の上昇が濃度依存的に認められた(図1)。また、滋養強壮素材として、朝鮮人参エキス末と比較した結果、馬心筋粉末は持続時間の延長が認められ、肉体疲労に対しての効果が示唆された。
なお、いずれの群も、同じ食餌を与えてある。また、mg/kgとは、マウスの体重あたりに換算した投与量である。
Anti-fatigue test;
Experiments with mice were conducted to evaluate the physical anti-fatigue action of horse myocardium powder. 30 mice (ddy, male, 6 weeks old) were divided into 5 groups: control group (Cont), ginseng extract powder (commercially available) group (100 mg), equine myocardium powder 50, 100, 200 mg / kg group. After breeding, each powder was dispersed in water and orally administered to mice at each dose once a day for 2 weeks. In the second week, a weight of 10% of the mouse body weight was loaded and a forced swimming experiment (the time until the head was completely submerged in water for 5 seconds was measured) was performed. Results At the measurement of the second week after administration, the horse myocardial powder administration group showed an increase in swimming duration in a concentration-dependent manner as compared to the control group (FIG. 1). In addition, as a nourishing tonic material, as compared with ginseng extract powder, horse myocardial powder was found to have an extended duration, suggesting an effect on physical fatigue.
All groups are fed the same diet. Moreover, mg / kg is the dose converted into the body weight of a mouse | mouth.
免疫力向上作用;
24匹のマウス(雌雄、4週齢)を、対照群、50mg/kg群、100mg/kg群、200mg/kg群の4群に分け、1週間、2週間、4週間後のマウス脾臓のNK細胞活性を測定した。NK細胞は投与1週間から馬心筋粉末の投与量が多くなるにつれて、高くなる傾向を示し、2週間、4週間投与200mg/kg群においては対照群に対して有意に高い値を示した(図2〜図4)。測定結果からマウス1匹あたり200mg/kg、2週間以上投与することによりNK活性が上昇することが示された。また、馬心筋粉末を継続的に摂取することで、免疫力を高める可能性が示唆された。
Immunity enhancing action;
Twenty-four mice (male and female, 4 weeks old) were divided into 4 groups of control group, 50 mg / kg group, 100 mg / kg group and 200 mg / kg group, and NK of spleen of mice after 1 week, 2 weeks and 4 weeks Cell activity was measured. NK cells tended to increase as the dose of equine myocardial powder increased from 1 week after administration, and showed a significantly higher value in the 200 mg / kg group administered for 2 weeks and 4 weeks than the control group (Fig. 2 to 4). From the measurement results, it was shown that NK activity was increased by administering 200 mg / kg per mouse for 2 weeks or more. In addition, it was suggested that continuous ingestion of equine myocardium powder may improve immunity.
本発明においては、ペプチド化された馬、又は、羊の心筋の本組成は高い分散性が有り、固形、錠剤、飲料、粉末、顆粒など、形態を問わず機能性、健康食品の素材として利用でき、また、他食品と配合することにより高い機能食品としての広範囲な利用ができる。 In the present invention, this composition of peptided horse or sheep myocardium has high dispersibility and is used as a material for functional, health foods, regardless of form, such as solids, tablets, beverages, powders, granules, etc. In addition, it can be widely used as a highly functional food by blending with other foods.
Claims (4)
前記酵素は、セリンプロテアーゼ、システインプロテアーゼ、又は、セリンプロテアーゼ及びシステインプロテアーゼのいずれかであることを特徴とする馬、又は、羊の心筋の酵素処理方法。 A method for enzymatic treatment of horse or sheep myocardium, in which an enzyme is processed stepwise on the basis of the properties of the enzyme in the same reaction tank for enzymatic degradation of the horse or sheep myocardium ,
Before SL enzymes are serine proteases, cysteine proteases, or a horse, characterized in that either serine proteases and cysteine proteases, or enzymatic treatment method for sheep myocardium.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009299070A JP5695826B2 (en) | 2009-12-29 | 2009-12-29 | Enzyme processing method for horse or sheep myocardium, food material, and health food for immunostimulation, tonicity, and metabolism promotion |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009299070A JP5695826B2 (en) | 2009-12-29 | 2009-12-29 | Enzyme processing method for horse or sheep myocardium, food material, and health food for immunostimulation, tonicity, and metabolism promotion |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011135843A JP2011135843A (en) | 2011-07-14 |
JP5695826B2 true JP5695826B2 (en) | 2015-04-08 |
Family
ID=44347954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009299070A Active JP5695826B2 (en) | 2009-12-29 | 2009-12-29 | Enzyme processing method for horse or sheep myocardium, food material, and health food for immunostimulation, tonicity, and metabolism promotion |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5695826B2 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2608051B1 (en) * | 1986-12-15 | 1989-04-07 | Bellon Labor Sa Roger | PROCESS FOR THE MANUFACTURE OF AN ENZYMATIC HYDROLYSATE OF PROTEINS RICH IN DI- AND TRI-PEPTIDES, FOR USE IN PARTICULAR IN ARTIFICIAL NUTRITION AND DIETETICS |
JPH02145525A (en) * | 1988-11-28 | 1990-06-05 | Sanwa Kagaku Kenkyusho Co Ltd | Stabilized essential oligopeptide composition and sleep stabilizer comprising same composition as main composition |
JP2736829B2 (en) * | 1991-08-07 | 1998-04-02 | 雪印乳業株式会社 | Production method of protein hydrolyzate without unpleasant taste |
JP3819454B2 (en) * | 1994-07-15 | 2006-09-06 | 日本たばこ産業株式会社 | Novel proline dipeptidase and method for hydrolyzing proteins and peptides using the proline dipeptidase |
JP2986764B2 (en) * | 1997-07-04 | 1999-12-06 | 明治乳業株式会社 | Method for preparing high-fischer-ratio peptide with low bitter amino acid composition close to human milk |
JP2007051090A (en) * | 2005-08-18 | 2007-03-01 | Pharma Foods International Co Ltd | Blood flow improving agent containing egg white peptide as active ingredient |
JP2007295842A (en) * | 2006-04-28 | 2007-11-15 | Dainippon Ink & Chem Inc | Method for preparation of peptide with angiotensin-converting enzyme inhibiting activity |
EP1967524A1 (en) * | 2007-03-06 | 2008-09-10 | Friesland Brands B.V. | Methods for producing ACE-inhibitory peptides from whey and peptides obtained thereby |
-
2009
- 2009-12-29 JP JP2009299070A patent/JP5695826B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2011135843A (en) | 2011-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104540960B (en) | The manufacture method of collagen peptide composition, 4 Inhibitorses of DPP and blood glucose value raise inhibitor | |
Gong et al. | Mechanisms of plastein formation, and prospective food and nutraceutical applications of the peptide aggregates | |
WO2017076112A1 (en) | Oyster peptide capable of enhancing sexual function, and preparation method and application thereof | |
CN101466389A (en) | Formulation comprising whey protein and hydrolysates for improving muscle recovery | |
WO2007091678A1 (en) | Rheumatoid arthritis-preventive agent for oral intake | |
Zhao et al. | Ultrasound treatment on the structure of goose liver proteins and antioxidant activities of its enzymatic hydrolysate | |
Wang et al. | Antihypertensive effect of rapeseed peptides and their potential in improving the effectiveness of captopril | |
JP5687697B2 (en) | Fish protein hydrolyzate for use in inhibiting weight gain and / or weight loss | |
WO2018021471A1 (en) | Food composition for improving brain function | |
Fadimu et al. | Enhancing the biological activities of food protein-derived peptides using non-thermal technologies: A review | |
CN104480176A (en) | Silver carp DPP-IV inhibitory polypeptide and applications thereof | |
Tacias-Pascacio et al. | Peptides with biological and technofunctional properties produced by bromelain hydrolysis of proteins from different sources: A review | |
JP2012116773A (en) | Igf-1 value-elevating agent | |
Yuan et al. | Sustainable utilization of proteins from fish processing by-products: Extraction, biological activities and applications | |
JP5695826B2 (en) | Enzyme processing method for horse or sheep myocardium, food material, and health food for immunostimulation, tonicity, and metabolism promotion | |
CN112401213A (en) | Potato peptide Maillard reaction product and preparation method and application thereof | |
CN108796016B (en) | Walnut peptide and enzymolysis extraction method thereof | |
CN101589823A (en) | A kind of production technology of sea cucumber health milk | |
JP2011116761A (en) | Antioxidative peptide derived from royal jelly | |
Akbarbaglu et al. | Physicochemical characteristics and antioxidant stability of spray‐dried soy peptide fractions | |
Wang et al. | Mechanisms and applications of milk‐derived bioactive peptides in food for special medical purposes | |
JP5312780B2 (en) | Food / drink and pharmaceutical composition for reducing blood ammonia concentration | |
Patil et al. | Biofunctional properties of milk protein derived bioactive peptides-A review | |
JP2009284798A (en) | Method for producing dipeptidyl peptidase iv inhibitor | |
JP2005040128A (en) | Biological method for obtaining food modifier based on heme iron, and food modifier to be obtained by the method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20111222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111222 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120713 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140304 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140502 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141021 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150120 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150209 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5695826 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |